Receptos, Inc. (NASDAQ:RCPT) most recently reported quarterly actual earnings per share of $N/A for the period ending on N/A. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $N/A. The difference between the estimate and the actual EPS was $N/A creating a surprise factor of N/A%. Currently, the company has an impact score of 91. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $N/A on the shares. The most bullish brokerage firm has a $N/A target, while the most bearish sees the stock headed towards $N/A. This is according to the N/A estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of N/A. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were N/A recommendations taking into account in order to arrive at this number. Of the N/A, N/A have a Strong Buy rating and N/A are rating it a Buy.

Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company’s product candidates span three specialty disease areas. The Company’s lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology. As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS.

Receptos, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.